Premium
Responsiveness of platelets and coronary arteries from different species to synthetic thromboxane and prostaglandin endoperoxide analogues
Author(s) -
Burke Sandra E.,
Lefer Allan M.,
Nicolaou Kyriacos C.,
Smith Gordon M.,
Smith J. Bryan
Publication year - 1983
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.1983.tb09393.x
Subject(s) - thromboxane a2 , platelet , cats , thromboxane , guinea pig , chemistry , prostaglandin , prostaglandin h2 , thromboxane b2 , medicine , pharmacology , constriction , endocrinology , fissipedia , thromboxane receptor , biochemistry
1 Platelet‐rich plasma (PRP) from humans, cats, dogs (after addition of 10 μ m adrenaline), rabbits and guinea‐pigs aggregated in response to sodium arachidonate or 9,11‐azo‐prostaglandin H 2 , while PRP obtained from sheep was unresponsive to either agent. 2 The stable thromboxane (Tx) analogues, carbocyclic TxA 2 (CTA 2 ) and pinane TxA 2 (PTA 2 ) significantly inhibited these aggregatory responses in platelets from humans, dogs and guinea‐pigs, while PTA 2 but not CTA 2 produced significant inhibition in cat platelets. The aggregatory response of PRP from rabbits was not significantly blocked by either analogue. 3 CTA 2 and the endoperoxide analogue 9,11‐methanoepoxy PGH 2 (U‐46619) constricted coronary arteries from cats, dogs, rabbits and guinea‐pigs, while sheep vessels were unresponsive to either analogue. 4 Vasoconstrictor responses to U‐46619 were significantly attenuated by PTA 2 in vessels from all species. However, constriction produced by CTA 2 was blocked significantly only in vessels from cats, dogs and guinea‐pigs. 5 These results demonstrate the species differences which exist in the responsiveness of platelets and coronary arteries to thromboxane and endoperoxide analogues. Furthermore, the results illustrate the importance of species selection in the study of thromboxane antagonists for potential therapeutic use.